Possible mechanisms of the formation of chronic fatigue syndrome in the clinical picture of multiple sclerosis

Neuroscience and Behavioral Physiology

Volumn 37, Issue 3, 2007, Pages 215-219

  Kasatkin, D S ^a   Spirin, N N ^a  

^a YAROSLAVL STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Chronicfatigue syndrome; Multiple sclerosis

Indexed keywords

3,4 DIAMINOPYRIDINE; AMANTADINE; FLUOXETINE; LEVACECARNINE; MODAFINIL; PEMOLINE; SERTRALINE;

ARTICLE; ASTHENIA; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC FATIGUE SYNDROME; CLINICAL FEATURE; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG MECHANISM; FATIGUE; GENETIC RISK; HUMAN; INSOMNIA; MOOD DISORDER; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; NORADRENERGIC SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; REMISSION; RESTLESS LEGS SYNDROME; RISK ASSESSMENT; RISK FACTOR; SEROTONINERGIC SYSTEM; SLEEP THERAPY; SYMPTOM;

AFFECTIVE SYMPTOMS; FATIGUE SYNDROME, CHRONIC; HUMANS; MULTIPLE SCLEROSIS;

EID: 33947361109     PISSN: 00970549     EISSN: 1573899X     Source Type: Journal    
DOI: 10.1007/s11055-007-0004-9     Document Type: Article

References (74)

1. A. S. Avedisova, L. S. Kanaeva, D. F. Ibragimov, and N. V. Lyupaeva, "Non-specific, psychological, and biological predictors of the efficacy of therapy with antidepressants in patients with depressive disorders (analytical review, part 2)," Psikhiat. Psikhofarmakoter., 5, 22-24 (2003).
2. V. B. Lantsova, L. Sh. Askarova, E. K. Sepp, and I. A. Zavalishin, "The role of acetylcholine receptors in the pathogenesis of autoimmune and neurodegenerative disorders of the nervous system," Neiroimmunologiya, 1, 80 (2003).
3. Extrapyramidal Disorders: Handbook of Diagnosis and Treatment [in Russian], V. N. Shtok, I. A. Ivanova-Smolenskaya, and O. S. Levin (eds.), MEDpress-Inform, Moscow (2002).
4. N. Afari and D. Buchwald, "Chronic fatigue syndrome: A review," Amer. J. Psychiat., 160, 221-236 (2003).
5. A. K. Afifi and R. A. Bergman, Functional Neuroanatomy, McGraw-Hill, New York (1998).
6. M. Altemus, I. Licino, L. Iolkovsky, and P. W. Gold, "Stimulation of the hypothalamic-pituital-adrenal axis by bulimic behaviors," Amer. Psychiatr. Ass., 378 (1992).
7. R. Bakshi, R. S. Miletich, K. Henschel, et al., "Fatigue in multiple sclerosis: Cross-sectional correlation with brain MRI findings in 71 patients," Neurology, 53, 1151-1155 (1999).
8. R. Bakshi, Z. A. Shaikh, R. S. Miletich, et al., "Fatigue in multiple sclerosis and its relationship to depression and neurologic disability," Mult. Scler., 6, 181-185 (2000).
9. S. A. Brod, G. D. Marshall, E. M. Henninger, et al., "Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis," Neurology, 46, 1633-1638 (1996).
10. D. Buchwald, M. H. Wener, T. Pearlman, et al., "Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome," J. Rheumatol., 24, 372-376 (1997).
11. B. Casanova, F. Coret, and L. Landede, "A study of various scales of fatigue and impact on the quality of life among patients with multiple sclerosis," Rev. Neurol., 30, 1235-1241 (2000).
12. C. C. Chao, E. N. Janoff, S. X. Hu, et al., "Altered cytokine release in peripheral blood mononuclear cell cultures from patients with chronic fatigue syndrome," Cytokine, 3, 292-298 (1991).
13. C. M. Clark, J. A. Fleming, D. Li, et al., "Sleep disturbance, depression, and lesion site in patients with multiple sclerosis," Arch. Neurol., 49, 641-643 (1992).
14. R. Cohen and M. Fisher, "Amantadine treatment of fatigue associated with MS," Arch. Neurol., 46, 676-680 (1989).
15. B. Colombo, F. M. Boneschi, P. Rossi, et al., "MRI and motor evoked potential findings in nondisabled multiple sclerosis with and without fatigue," J. Neurol., 247, 506-509 (2000).
16. M. J. Craner, A. C. Lo, J. A. Black, et al., "Abnormal sodium channel distribution in optic nerve axons in a model of inflammatory demyelination," Brain, 126, 1552-1561 (2003).
17. M. A. Demitrack, J. K. Dale, S. E. Straus, et al., "Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome," J. Cin. Endocrinol. Metab., 73, 1224-1234 (1991).
18. S. D. M. Drakulic, J. Jevdjic, B. Milicic, et al., "Fatigue in patient with multiple sclerosis: Relationship to disease pattern, disability, and depression," Eur. J. Neurol., 9, Suppl. 2, 321-322 (2002).
19. R. Du Boistesselin, "Hydrotherapeutics and biophysiological developments. Roles of certain regulatory structures in asthenia: detection of Arcalion binding by histofluorescence," Gaz. Med., 95, Suppl. 3, 21-24 (1988).
20. S. Endres et al., "Interleukin-1 in the pathogenesis of fever," Eur. J. Clin. Invest., 17, 469-474 (1987).
21. C. Feuerstein, "Neurophysiological data concerning fatigue. Role of activator reticular formation," Entret. Bichat., Hors-Serie, 11-19 (1992).
22. M. Filippi, M. A. Rocca, B. Colombo, et al., "Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis," Neuroimage, 15, 559-567 (2002).
23. J. D. Fisk, A. Pontefract, P. G. Ritvo, et al., "The impact of fatigue on patients with multiple sclerosis," Can. J. Neurol. Sci., 21, 9-14 (1994).
24. P. Flachenecker, A. Wolf, M. Krauser, et al., "Cardiovascular autonomic dysfunction in multiple sclerosis: Correlation with orthostatic intolerance," J. Neurol., 2346, 578-586 (1999).
25. H. Ford, P. Trigwell, and M. Johnson, "The nature of fatigue in multiple sclerosis," J. Psychosom. Res., 45, 33-34 (1998).
26. J. E. Freal, G. H. Kraft, and J. K. Coryell, "Symptomatic fatigue in multiple sclerosis," Arch. Phys. Med. Rehabil., 65, 135-138 (1984).
27. T. Fukuzawa, H. Sasaki, S. Kikuchi, et al., "Serum carnitine and disabling fatigue in multiple sclerosis," Psychiat. Clin. Neurosci., 50, 323-325 (1996).
28. C. Gemma, "Activation of the hypothalamic serotoninergic system by central interleukin-1," Eur. J. Pharmacol., 209, 139-140 (1991).
29. M. Gottschalk, T. Kumpfel, P. Flachenecker, et al., "Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis," Arch. Neurol., 62, 277-280 (2005).
30. P. Hautecoeur, G. Forzy, P. Gallois, et al., "Variations of 1L2, 1L6, TNF alpha plasmatic levels in relapsing remitting multiple sclerosis," Acta Neurol. (Belg.), 97, 240-243 (1997).
31. C. Heesen, S. M. Gold, A. Raji, et al., "Cognitive impairment correlates with hypothalamo-pituitary-adrenal axis dysregulation in multiple sclerosis," Psychoneuroendocrinology, 27, 505-517 (2002).
32. I. Huitinga, M. van der Cammen, L. Salm, et al., "IL-lβ immunoreactive neurons in the human hypothalamus: Reduced numbers in multiple sclerosis," J. Neuroimmun., 107, 8-20 (2000).
33. J. Iriarte and P. de Castro, "Correlation between symptom fatigue and muscular fatigue in multiple sclerosis," Eur. J. Neurol., 5, 579-585 (1998).
34. J. Iriarte, M. L. Subira, and P. Castro, "Modalities of fatigue in multiple sclerosis: Correlation with clinical and biological factors," Mult. Scler., 6, 124-130 (2000).
35. J. A. Kent-Braun, K. R. Sharma, R. G. Miller, et al., "Postexercise phosphocreatine resynthesis is slowed in multiple sclerosis," Muscle Nerve, 17, 835-841 (1994).
36. D. C. Kroencke, S. G. Lynch, and D. R. Denney, "Fatigue in multiple sclerosis: Relationship to depression, disability, and disease pattern," Mult. Scler., 6, 131-136 (2000).
37. L. B. Krupp, L. A. Alvarez, N. G. LaRocca, et al., "Fatigue in multiple sclerosis," Arch. Neurol., 45, 435-437 (1988).
38. L. B. Krupp, L. A. Alvarez, N. G. LaRocca, et al., "Fatigue in multiple sclerosis," Arch. Neurol., 46, 841-842 (1989).
39. L. B. Krupp, P. K. Doyle, C. Doscher, et al., "Fatigue therapy in multiple sclerosis: Results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo," Neurology, 45, 1956-1961 (1995).
40. J. F. Kurtzke, "On the evaluation of disability in multiple sclerosis," Neurology, 2, 686-694 (1961).
41. E. M. Martinez-Caceres, J. Rio, M. Barrau, et al., "Amelioration of flu-like symptoms at the onset of interferon beta-lb therapy in multiple sclerosis by low-dose oral steroids is related to a decrease in interleukin-6 induction," Ann. Neurol., 44, 682-685 (1998).
42. C. J. Mathias, R. Mallipeddi, and K. Bleasdale-Barr, "Symptoms associated with orthostatic hypotension in pure autonomic failure and multiple system atrophy," J. Neurol., 246, 893-898 (1999).
43. W. I. McDonald and T. A. Sears, "The effects of experimental demyelination on conduction in the central nervous system," Brain, 93, 583-598 (1970).
44. S. Merkelbach, U. Dillman, C. Kölmel, et al., "Cardiovascular autonomic dysregulation and fatigue in multiple sclerosis," Mult. Scler., 7, 320-326 (2001).
45. L. M. Metz, S. B. Patten, S. M. Rose, et al., "Multiple sclerosis fatigue is decreased at 6 months by glatiramer acetate (Copaxone)," J. Neurol., 248, Suppl. 2, 115 (2001).
46. L. M. Metz, S. B. Patten, and C. J. Archibald, "The effect of immunomodulatory treatment on multiple sclerosis fatigue," J. Neurol. Neurosurg. Psychiat., 75, 1045-1047 (2004).
47. D. C. Mohr, A. C. Boudewyn, D. E. Goodkin, et al., "Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis," J. Consult. Clin Psychol., 69, 942-949 (2001).
48. Multiple Sclerosis Council for Clinical Practice Guidelines (1988).
49. Multiple Sclerosis Therapeutics, R. A. Rudick and D. E. Goodkin (eds.), London (2000).
50. T. J. Murray, "Amantadine therapy for fatigue in multiple sclerosis," Can. J. Neurol. Sci., 12, 251-254 (1985).
51. K. W. Rammohan, J. H. Rosenberg, D. J. Lynn, et al., "Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: A two centre phase 2 study," J. Neurol. Neurosurg. Psychiatr., 72, 179-183 (2002).
52. A. T. Reder, R. L. Makowiec, and M. T. Lowy, "Adrenal size is increased in multiple sclerosis," Arch. Neurol., 51, 151-154 (1994).
53. U. Roelcke, L. Kappos, J. Lechner-Scott, et al., "Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: A 18F-fluorodeoxyglucose positron emission tomography study," Neurology, 48, 1566-1571 (1997).
54. G. A. Rosenberg and O. Appenzeller, "Amantadine, fatigue, and multiple sclerosis," Arch. Neurol., 45, 1104-1106 (1988).
55. A. Ruger, P. Flachenecker, C. Hippel, et al., "Fatigue in multiple sclerosis is related to dysfunction of the sympathic nervous system," ENS (Berlin) (2002).
56. M. A. Schaeffer and A. Baum, "Adrenal cortical response to stress at Three Mile Island," Psychosom. Med., 46, 175-181 (1984).
57. C. E. Schwartz, L. Coulthard-Morris, and Q. Zeng, "Psychosocial correlates of fatigue in multiple sclerosis," Arch. Phys. Med. Rehabil., 77, 165-170 (1996).
58. S. R. Schmid, M. D. Petrie, M. P. McDermott, et al., "Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis," Neurology, 48, 817-821 (1997).
59. S. R. Schmid, M. Covington, B. M. Segal, et al., "Fatigue in multiple sclerosis: Current understanding and future directions," J. Rehabil. Res. Dev., 39, 211-224 (2002).
60. G. L. Sheean, N. M. Murray, J. C. Rothwell, et al., "An open-labelled clinical and electrophysiological study of 3,4-diaminopyridine in the treatment of fatigue in multiple sclerosis," Brain, 121, 967-975 (1998).
61. D. F. Swaab, A.-M. Bao, and P. J. Lucassen, "The stress system in the human brain in depression and neurodegeneration," Ageing Res. Rev., 4, 141-194 (2005).
62. M. Takamori and S. Okumura, "Presynaptic modulation of neuromuscular transmission by acetylcholine receptor antibody: myasthenic serum and monoclonal antibody produced by transformed lymphocytes," Neurology, 36, 942-947 (1986).
63. V. Tomassini, E. Onesti, P. Paseualetti, et al., "Acetyl-L-carnitine treatment of fatigue in multiple sclerosis," Eur. J. Neurol., 9, Suppl. 2, 3199 (2002).
64. V. Tomassini, C. Pozzilli, E. Onesti, et al., "Comparison of the effects of acetyl-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: Results of a pilot, randomised, double-blind, crossover trial," J. Neurol. Sci., 218, 103-108 (2004).
65. S. J. Tzartos, D. Sophianos, and A. Efthimiadis, "Role of the main immunological region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protect against antigenic modulation by human sera," J. Immunol., 134, 2343-2349 (1985).
66. W. M. van der Kamp, M. Noordhout, P. O. Thomson, et al., "Correlation of phasic muscle strength and corticomotoneuron conduction time in multiple sclerosis," Ann. Neurol., 29, 6-12 (1991).
67. M. Vieren, B. D'Hooghe, and H. Carton, "The use of 5-methoxypsoralen for fatigue and other symptoms in MS," J. Neuroimmun., 54, 56-63 (1995).
68. S. G. Waxman, "Clinicopathological correlation in multiple sclerosis and related diseases," Adv. Neurol., 31, 169-182 (1981).
69. W. Wieling and J. M. Karemaker, "Measurement of heart rate and blood pressure to evaluate disturbances in neurocardiovascular control, in: Autonomic Failure. A Textbook of Clinical Disorders of the Autonomic Nervous System, C. J. Mathias and R. Bannister (eds.), Oxford University Press, New York, 4th edition (1999).
70. E. Willoughby, "Modafinil for fatigue in multiple sclerosis," J. Neurol. Neurosurg. Psychiat., 72, 150 (2002).
71. S. A. Wulff, E. Calabresi, and A. Allie, "The Kv1.3 potassium channel as a target for multiple sclerosis," J. Clin. Invest., 111, 1703-1713 (2003).
72. X. Xu, H. Zhang, H. Guo, et al., "Clinical neuroimmunology," Adv. Neuroimmunol., 6, No. 3, 249-257 (1996).
73. R. Yehuda, H. Resnick, G. Kahana, et al., "Long-lasting hormonal alterations to extreme stress in humans: Normative or maladaptive," Psychosom. Med., 55, 287-297 (1993).
74. A. H. Young, M. Sharpe, A. Clements, et al., "Basal activity of the hypothalamic-pituitary-adrenal axis in patients with the chronic fatigue syndrome (neurasthenia)," Biol. Psychiat., 43, 236-237 (1998).